Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus FOLFOX in Advanced HER2- Gastroesophageal Adenocarcinomas
NCT07070466Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in gastroesophageal adenocarcinoma, sponsored by Massachusetts General Hospital. Started Oct 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT07070466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070466.